Gland Pharma, evolving from a contract manufacturer to a global leader in injectables, stands at the forefront of the pharmaceutical landscape, navigating complexities with precision. Operating across 60 countries, including pivotal markets like the United States, Europe, and India, Gland Pharma’s business-to-business model underscores its prowess in developing, manufacturing, and marketing complex injectables. The strategic acquisition of Cenexi in Europe and the foray into biosimilar Contract Development and Manufacturing Operations (CDMO) showcase the company’s commitment to innovation.
In an industry where precision is paramount, Gland Pharma’s focus on the global stage, especially in China, aligns with its exponential growth trajectory. The article delves beyond statistics, unraveling the intricate market dynamics, the company’s outstanding performance, and the broader economic currents. Gland Pharma is stepping into new areas, like making biosimilar drugs and growing its plasma protein offerings. This exciting journey brings a sense of promise. Can Gland Pharma’s stock price go up to 3k?
About Gland Pharma Ltd
Established in 1978 in Hyderabad, India, Gland Pharma has evolved into a premier injectables manufacturing company, boasting a global presence in 60 countries, including significant markets like the United States, Europe, Canada, Australia, and India. Underpinned by a robust business-to-business (B2B) model, we have garnered recognition for our excellence in the development, manufacturing, and marketing of complex injectables, spanning sterile injectables, oncology, and ophthalmic segments.
Promoted by Shanghai Fosun Pharma, a global pharmaceutical major, Gland Pharma has achieved remarkable milestones, launching 14 molecules in the market, including notable ones like Calcitriol, Fluphenazine, and Desmopressin. Our commitment to innovation is reflected in the increased volume of key products such as Ketorolac Tromethamine, Rocuronium, Fluorouracil, and Esmolol.
With a portfolio encompassing liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops, we are expanding our manufacturing capabilities to include complex injectables like peptides, long-acting injectables, suspensions, and hormonal products. Furthermore, we are venturing into new delivery systems such as pens and cartridges, demonstrating our dedication to diverse and evolving healthcare needs.
Backed by a professional management team, Gland Pharma stands as a beacon of pharmaceutical research and development. Our focus on quality, affordability, and future-oriented solutions has led us to successfully harness research and development expertise, producing niche products for varied markets. As we continue to grow exponentially, Gland Pharma remains at the forefront of the pharmaceutical industry, delivering high-quality injectables that cater to the dynamic demands of global healthcare.
Recent News Around Gland Pharma Ltd
- Gland Pharma experiences a 3.6% stock surge as the US FDA concludes its inspection at the Hyderabad plant, held from August 23rd to 26th, 2023.
- In the trade spotlight, Gland Pharma shows positive indicators with a consolidation breakout and a long bullish candlestick pattern on the daily scale.
- The company secures a tentative USFDA nod for a blood pressure medication, claiming first-to-file status and potential eligibility for a 180-day generic drug exclusivity.
- Motilal Oswal expresses bullish sentiments on Gland Pharma, recommending a buy rating with a target price of Rs 1920 in a November 6, 2023 research report. The company is noted for being almost debt-free.
- Despite consistent profitability, Gland Pharma refrains from paying dividends, prompting observations about its capital allocation and distribution policies.
Gland Pharma Ltd Q2 Fy2024 Key Points And Summary:
- Gland Pharma Ltd reported robust financial performance in Q2 FY24, with a YoY revenue growth of 32%, reaching INR 13,734 million.
- The gross margin showed a significant increase, reaching INR 8,519 million with a margin of 62%, reflecting strong operational efficiency.
- EBITDA for the quarter was INR 3,205 million, with a margin of 23%, showcasing a steady growth trajectory.
- Profit Before Tax (PBT) stood at INR 2,899 million, with a margin of 21%, indicating sound financial management despite a slight YoY decline.
- Profit After Tax (PAT) was INR 1,941 million, with a margin of 14%, demonstrating resilience amid market fluctuations.
- The company’s QoQ performance remained stable, with revenue from operations at INR 3,588 million, gross margin at 77%, and EBITDA margin at -7%.
- The financials include results from the recent inclusion of Cenexi, impacting the comparability with previous periods.
- The financial highlights underscore Gland Pharma’s commitment to navigating market complexities and delivering value to its stakeholders.
Shareholding Pattern Gland Pharma Ltd
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | |
| Promoters + | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% |
| FIIs + | 4.67% | 4.33% | 2.80% | 4.91% | 4.05% |
| DIIs + | 23.13% | 23.23% | 23.38% | 22.45% | 24.17% |
| Public + | 14.35% | 14.59% | 15.97% | 14.78% | 13.93% |
| No. of Shareholders | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 |
Gland Pharma Ltd’s shareholding pattern has exhibited noteworthy trends over the specified quarters of the fiscal year 2023. As of December 2022, the promoters maintained a consistent stronghold with a stake of 57.86%, indicating a steadfast commitment to the company. In subsequent quarters, the promoter’s holding remained unaltered.
Foreign Institutional Investors (FIIs), however, showed some volatility in their stake. Starting at 4.67% in December 2022, their shareholding experienced fluctuations, reaching its lowest at 2.80% in June 2023. This decline was followed by a rebound to 4.91% in September 2023, reflecting a dynamic engagement.
Domestic Institutional Investors (DIIs) displayed a relatively stable trajectory, hovering around the 23% mark throughout the analyzed period. This steadfast interest from DIIs suggests confidence in Gland Pharma’s prospects.
Contrarily, public shareholding witnessed fluctuations. After a minor increase from 14.35% in December 2022 to 14.59% in March 2023, it showed a declining trend, reaching 13.93% by December 2023. This reduction may signify shifts in retail investor sentiment or strategic moves by institutional investors.
The number of shareholders increased from 1,48,469 in December 2022 to 1,81,747 in June 2023, indicating a surge in the company’s investor base. However, this trend reversed in subsequent quarters, dropping to 1,36,021 by December 2023.
In summary, Gland Pharma’s shareholding pattern reflects a consistent promoter holding, fluctuations in FII interest, stable DII confidence, and variable public participation. The evolving number of shareholders underscores changing market dynamics and investor sentiment, necessitating a closer examination of the company’s strategic developments.
Gland Pharma Ltd Share Price Target 2024 To 2030
Gland Pharma Ltd Share Price Target 2024
| When | Maximum Price | Minimum Price |
| January 2024 | ₹2,133.69 | ₹1,855.39 |
| February 2024 | ₹2,177.24 | ₹1,893.25 |
| March 2024 | ₹2,221.67 | ₹1,931.89 |
| April 2024 | ₹2,156.96 | ₹1,875.62 |
| May 2024 | ₹2,125.09 | ₹1,847.90 |
| June 2024 | ₹2,201.59 | ₹1,914.43 |
| July 2024 | ₹2,179.57 | ₹1,895.28 |
| August 2024 | ₹2,266.76 | ₹1,971.09 |
| September 2024 | ₹2,357.43 | ₹2,049.94 |
| October 2024 | ₹2,311.20 | ₹2,009.74 |
| November 2024 | ₹2,380.54 | ₹2,070.04 |
| December 2024 | ₹2,440.05 | ₹2,121.79 |
In 2024, Gland Pharma’s share price is poised for a dynamic trajectory, with expected maximum and minimum prices for each month. Commencing in January, the expected price will only range between ₹1,855.39 and ₹2,133.69, reflecting an optimistic outlook. This upward trend is anticipated to persist through the year, with gradual increments month by month. February is expected to witness a marginal increase, with the price ranging from ₹1,893.25 to ₹2,177.24. March is projected to continue this trend, reaching ₹2,221.67 at the maximum and ₹1,931.89 at the minimum. Investors can anticipate a potential peak in December, with the expected maximum reaching ₹2,440.05 and the minimum at ₹2,121.79.
These projections are informed by comprehensive market analysis, considering factors such as industry trends, Gland Pharma’s historical performance, and broader economic indicators. Investors should stay attuned to these anticipated prices, recognizing their dependency on evolving market conditions and Gland Pharma’s strategic moves throughout the year.
Gland Pharma Ltd Share Price Target 2025
| when | Maximum Price | Minimum Price |
| January 2025 | ₹2,488.85 | ₹1,914.50 |
| February 2025 | ₹2,552.67 | ₹1,963.59 |
| March 2025 | ₹2,652.23 | ₹2,040.17 |
| April 2025 | ₹2,600.22 | ₹2,000.17 |
| May 2025 | ₹2,524.49 | ₹1,941.91 |
| June 2025 | ₹2,638.09 | ₹2,029.30 |
| July 2025 | ₹2,586.36 | ₹1,989.51 |
| August 2025 | ₹2,666.35 | ₹2,051.04 |
| September 2025 | ₹2,759.67 | ₹2,122.83 |
| October 2025 | ₹2,831.43 | ₹2,178.02 |
| November 2025 | ₹2,902.21 | ₹2,232.47 |
| December 2025 | ₹2,974.77 | ₹2,288.28 |
In 2025, Gland Pharma’s share price is expected to exhibit a progressive trend, offering investors a range of potential values for each month. January is anticipated to open with a minimum price of ₹1,914.50 and a maximum of ₹2,488.85, setting a positive tone for the year. This upward trajectory is foreseen to continue, with February witnessing a range of ₹1,963.59 to ₹2,552.67. March is expected to see further growth, reaching a maximum of ₹2,652.23 and a minimum of ₹2,040.17.
As the year unfolds, investors can monitor the market in anticipation of April, with projected prices between ₹2,000.17 and ₹2,600.22. The optimistic trend persists, with the maximum price reaching ₹2,974.77 and the minimum at ₹2,288.28 in December. These forecasts are rooted in a comprehensive analysis of industry dynamics, historical performance, and macroeconomic indicators, providing stakeholders with valuable insights into potential future price movements.
Gland Pharma Ltd Share Price Target 2026 To 2030
| Year | Maximum Price | Minimum Price |
|---|---|---|
| 2026 | ₹3,123.51 | ₹2,186.45 |
| 2027 | ₹3,435.86 | ₹2,405.10 |
| 2028 | ₹4,810.20 | ₹2,405.10 |
| 2029 | ₹4,164.67 | ₹2,082.34 |
| 2030 | ₹5,414.08 | ₹3,789.85 |
In the coming years, Gland Pharma’s share price is anticipated to undergo notable fluctuations, offering investors a spectrum of potential values. Commencing in 2026, the projected maximum and minimum prices reflect an optimistic trajectory, with the expected range between ₹2,186.45 and ₹3,123.51. As we move into 2027, the forecast suggests a further increase, reaching a maximum of ₹3,435.86 and a minimum of ₹2,405.10.
The trend continues into 2028, where the share price is expected to exhibit significant growth, ranging from ₹2,405.10 to ₹4,810.20. Investors should closely monitor the market in 2029, as the maximum price is projected at ₹4,164.67 and the minimum at ₹2,082.34. Looking towards 2030, the share price is anticipated to peak at ₹5,414.08, with a minimum of ₹3,789.85.
These projections are based on comprehensive market analysis, considering factors such as industry trends, historical performance, and broader economic indicators. Investors are advised to stay informed and agile in response to evolving market conditions.
Gland Pharma Ltd ‘s Financial Condition (Last 5 Years)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
| Sales + | 2,044 | 2,633 | 3,463 | 4,401 | 3,617 | 3,606 |
| Expenses + | 1,338 | 1,678 | 2,161 | 2,890 | 2,598 | 2,546 |
| Operating Profit | 706 | 955 | 1,302 | 1,511 | 1,019 | 1,060 |
| OPM % | 35% | 36% | 38% | 34% | 28% | 29% |
| Other Income + | 66 | 139 | 135 | 224 | 184 | 120 |
| Interest | 4 | 7 | 3 | 5 | 7 | 7 |
| Depreciation | 82 | 95 | 99 | 110 | 147 | 154 |
| Profit before tax | 686 | 993 | 1,335 | 1,619 | 1,048 | 1,018 |
| Tax % | 34% | 22% | 25% | 25% | 26% | |
| Net Profit + | 452 | 773 | 997 | 1,212 | 776 | 752 |
| EPS in Rs | 291.65 | 49.88 | 60.94 | 73.78 | 47.11 | 45.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Gland Pharma Ltd has demonstrated a dynamic financial performance over the past five years, showcasing a robust growth trajectory and resilient operational efficiency. The company’s sales have experienced steady expansion, climbing from ₹2,044 crore in March 2019 to ₹3,606 crore in the trailing twelve months (TTM). This growth underscores Gland Pharma’s success in capturing market opportunities and expanding its revenue base.
Despite an increase in expenses over the years, the company has effectively managed its operating costs, maintaining a healthy operating profit margin (OPM). The OPM, which stood at 35% in March 2019, has consistently remained above 28% in subsequent years, reflecting the company’s operational excellence. However, there has been a slight dip in OPM in recent periods, indicating the impact of evolving market dynamics.
Other income, comprising non-operating revenues, has contributed positively to the company’s overall profitability. Although interest and depreciation have seen marginal increases, they remain at manageable levels. The profit before tax (PBT) has followed an upward trajectory, reaching ₹1,018 crore in the TTM.
The company’s tax efficiency has been notable, with a consistent tax rate ranging from 22% to 26% over the years. This tax discipline has contributed to sustaining healthy net profit margins. Gland Pharma’s net profit, despite fluctuations, has surpassed ₹752 crore in the TTM, showcasing resilience amid industry challenges.
Earnings per share (EPS) have seen variations, influenced by factors like increased share capital. The dividend payout percentage has consistently been at 0%, indicating a strategic approach to capital allocation, possibly reinvesting profits for future growth initiatives.
In conclusion, Gland Pharma’s financial performance reflects a company navigating competitive markets effectively, adapting to changes, and maintaining a strong financial position. Investors should continue to monitor the company’s strategies and market dynamics for informed decision-making.
FAQS
What is Gland Pharma Ltd?
Gland Pharma Ltd is a pharmaceutical company established in Hyderabad, India, in 1978. It started as a contract manufacturer of small volume liquid parenteral products and operates primarily under a business-to-business (B2B) model.
What is the current stock price of Gland Pharma Ltd?
The current stock price of Gland Pharma Ltd is ₹1,950 as of 18 Jan 4:03 p.m.
What is the market capitalization of Gland Pharma Ltd?
The market capitalization of Gland Pharma Ltd is ₹32,128 Crores.
What is the 52-week high and low for Gland Pharma Ltd?
The 52-week high for Gland Pharma Ltd is ₹2,058, and the 52-week low is ₹861.
What is the stock P/E ratio of Gland Pharma Ltd?
The stock P/E (Price/Earnings) ratio of Gland Pharma Ltd is 40.8.
What is the book value of Gland Pharma Ltd?
The book value of Gland Pharma Ltd is ₹510.
What is the dividend yield of Gland Pharma Ltd?
The dividend yield of Gland Pharma Ltd is 0.00%.
What is the Return on Capital Employed (ROCE) for Gland Pharma Ltd?
The Return on Capital Employed (ROCE) for Gland Pharma Ltd is 14.7%.
What is the Return on Equity (ROE) for Gland Pharma Ltd?
The Return on Equity (ROE) for Gland Pharma Ltd is 10.8%.
What is the face value of Gland Pharma Ltd’s stock?
The face value of Gland Pharma Ltd’s stock is ₹1.00.
Should one invest in Gland Pharma Ltd?
Gland Pharma Ltd, established in 1978, operates as one of the leading injectable-focused pharmaceutical companies globally, with a presence in 60 countries. Promoted by Shanghai Fosun Pharma, the company follows a business-to-business (B2B) model.
As of Q2 FY2024, Gland Pharma recorded a revenue of ₹1,011 crore, boasting a solid operating profit margin of 34%. The earnings per share (EPS) for the quarter stood at ₹15.64. The stock is currently trading at ₹1,950, reflecting a market capitalization of ₹32,128 crore.
With a price-to-earnings (P/E) ratio of 40.8, Gland Pharma’s stock indicates a premium valuation. The book value per share is ₹510, and the company does not offer a dividend yield. The Return on Capital Employed (ROCE) is a healthy 14.7%, showcasing efficient capital utilization.
The shareholding pattern underscores a consistent promoter holding of 57.86%. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) display fluctuating interest, with the public shareholding dropping from 14.35% in December 2022 to 13.93% by December 2023.
In the pharmaceutical sector, Gland Pharma’s P/E ratio of 40.85 positions it between peers like Torrent Pharma and Ajanta Pharma. The Return on Capital Employed (ROCE) at 14.68% aligns competitively within the industry.
Considering Gland Pharma’s robust financial performance and strategic market position, investors may find an opportunity for pharmaceutical industry exposure. However, the premium valuation and the absence of dividend payouts should be factored into investment decisions. The steady promoter holding contributes to the company’s overall stability. Investors should stay vigilant regarding pharmaceutical sector developments and the company’s expansion initiatives. In summary, Gland Pharma offers potential for investors seeking pharmaceutical industry exposure, but careful evaluation of valuation metrics is advisable.
Leave a Reply